Yung Lyou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9192756/publications.pdf

Version: 2024-02-01

23 papers	1,087 citations	933447 10 h-index	22 g-index
23	23	23	1701 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Prostate Cancer Characteristics and Outcomes after Prostatectomy in Asian-American Men. Clinical Genitourinary Cancer, 2022, 20, 92-92.e6.	1.9	2
2	Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma. Clinical Genitourinary Cancer, 2022, 20, 35-42.	1.9	5
3	Disruption of β-Catenin–Dependent Wnt Signaling in Colon Cancer Cells Remodels the Microenvironment to Promote Tumor Invasion. Molecular Cancer Research, 2022, 20, 468-484.	3.4	7
4	Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nature Medicine, 2022, 28, 704-712.	30.7	181
5	Wnt/ \hat{l}^2 -Catenin Signaling and Immunotherapy Resistance: Lessons for the Treatment of Urothelial Carcinoma. Cancers, 2021, 13, 889.	3.7	24
6	Hormonal manipulation in androgen signaling: a narrative review on using novel androgen therapy agents to optimize clinical outcomes and minimize side effects for prostate cancer patients. Translational Andrology and Urology, 2021, 10, 3199-3207.	1.4	6
7	Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma. JAMA Oncology, 2021, 7, 1536.	7.1	28
8	Advances in Immunotherapy and the TGF- \hat{l}^2 Resistance Pathway in Metastatic Bladder Cancer. Cancers, 2021, 13, 5724.	3.7	13
9	Reassessing the role of chemoimmunotherapy in chronic lymphocytic leukemia. Expert Review of Hematology, 2020, 13, 31-38.	2.2	5
10	Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1–3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3–altered Advanced/Metastatic Urothelial Carcinoma. European Urology, 2020, 78, 916-924.	1.9	18
11	Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis., 2020, 8, e000953.		32
12	Machine Learning–Based Interpretation and Visualization of Nonlinear Interactions in Prostate Cancer Survival. JCO Clinical Cancer Informatics, 2020, 4, 637-646.	2.1	52
13	Managing Bladder Cancer Care during the COVID-19 Pandemic Using a Team-Based Approach. Journal of Clinical Medicine, 2020, 9, 1574.	2.4	9
14	Defining Value in Metastatic Prostate Cancer: What Is the Cost of Living Longer and Better?. JCO Oncology Practice, 2020, 16, 53-54.	2.9	1
15	Disseminated Microinfarctions with Cerebral Microbleeds. Journal of Stroke and Cerebrovascular Diseases, 2018, 27, e95-e97.	1.6	2
16	Radiation-Associated Angiosarcoma of the Breast: A Case Report and Literature Review. Case Reports in Oncology, 2018, 11, 216-220.	0.7	10
17	Orbital Metastases from Breast Cancer with BRCA2 Mutation: A Case Report and Literature Review. Case Reports in Oncology, 2018, 11, 360-364.	0.7	2
18	Inhibition of nuclear Wnt signalling: challenges of an elusive target for cancer therapy. British Journal of Pharmacology, 2017, 174, 4589-4599.	5.4	48

Yung Lyou

#	Article	IF	CITATIONS
19	A Patient with Supraclavicular Lymphadenopathy and Anterior Mediastinal Mass Presenting as a Rare Case of Composite Lymphoma: A Case Report and Literature Review. Case Reports in Oncology, 2017, 9, 854-860.	0.7	2
20	Lactate/pyruvate transporter MCT-1 is a direct Wnt target that confers sensitivity to 3-bromopyruvate in colon cancer. Cancer & Metabolism, 2016, 4, 20.	5.0	63
21	Maturin is a novel protein required for differentiation during primary neurogenesis. Developmental Biology, 2013, 384, 26-40.	2.0	21
22	Generation of Functional Eyes from Pluripotent Cells. PLoS Biology, 2009, 7, e1000174.	5.6	60
23	Global Reorganization of Replication Domains During Embryonic Stem Cell Differentiation. PLoS Biology, 2008, 6, e245.	5.6	496